Orphazyme A/S (0CUM.L)

Orphazyme A/S (0CUM.L) — VMCI valuation read

Across 120 indicators, Orphazyme A/S (0CUM.L) lands at VMCI 40/100. The Healthcare sector median is 50, so the 10-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 0CUM.L in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 0CUM.L trades at 23.0x earnings, 28% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of 3.3x is the binding constraint on the bear case for 0CUM.L on the trailing balance sheet.

0CUM.L fell 2.0% over the trailing 7 days, with a -5.2% read on a 30-day basis.